{"id":40323,"date":"2017-09-15T08:01:30","date_gmt":"2017-09-15T12:01:30","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40323"},"modified":"2017-09-15T00:03:21","modified_gmt":"2017-09-15T04:03:21","slug":"verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323","title":{"rendered":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial"},"content":{"rendered":"<p><strong>Verastem Inc (NASDAQ:VSTM)<\/strong> announced recently that its new drug to treat selected blood cancer indications have met the essential goal of the late-stage study. The company said that the drug, duvelisib, reduces the risk associated with the disease progression or even death in patients by about 48% compared to the current, Novartis Arzerra drug available in the market.<\/p>\n<p>The oral drug was administered to the 319 patients who suffer from the Chronic Lymphocytic Leukemia (CLL) or the Small Lymphocytic Lymphoma (SLL) and was not responding to the initial treatment or are in the last stages of cancer. Both CLL and SLL affect the body cells in the immune system making them spread uncontrollably. Verastem intends to distribute the application for duvelisib in the first half of next year.<\/p>\n<p>According to Cantor Fitzgerald the analyst at Mara Goldstein, the study has revealed \u2018squarely positive\u2019 results suggesting a commercial opportunity that has not reflected in the company\u2019s stock price. Verastem\u2019s shares gained immediately after the announcement. Goldstein stated that the new drug could generate over $400 million in sales in the next five years after launch in the market.<\/p>\n<p>Furthermore, Duvelisib met the aim in testing the drug in treating the indolent non-Hodgkin&#8217;s lymphoma, a blood cancer that progresses slowly in the body cells according to Verastem. The latest drug has the potential to work best in a waning chemotherapy market. Verastem is planning to launch the mid-stage trial testing of duvelisib drug for treatment of Peripheral T-Cell Lymphoma (PTCL), a rare cancer which affects elderly people before the end of the year in both the US and Japan.<\/p>\n<p>Verastem focuses on research for and developing drugs that can improve the lives of the cancer patients and the expansion of duvelisib program has been granted the Fast Track designation by the United States Food and Drug Administration (FDA) for treatment of PTCL patients who have gone through at least prior therapy. The company has also appointed a new director to its board, Mr. Brian Stuglik who brings to Verastem over 35 years of experience in oncology management and has successfully launched various multi-billion dollar brands including the Gemzar\u00ae, Alimta,\u00ae and Erbitux\u00ae.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Verastem Inc (NASDAQ:VSTM) announced recently that its new drug to treat selected blood cancer indications have met the essential goal of the late-stage study. The [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":40324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2627,2626,10475],"stock_ticker":[],"class_list":["post-40323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqvstm","tag-verastem-inc-nasdaqvstm","tag-verastem-inc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Verastem Inc (NASDAQ:VSTM) announced recently that its new drug to treat selected blood cancer indications have met the essential goal of the late-stage study. The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-15T12:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial\",\"datePublished\":\"2017-09-15T12:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg\",\"keywords\":[\"NASDAQ:VSTM\",\"Verastem Inc (NASDAQ:VSTM)\",\"Verastem Inc.\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\",\"name\":\"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg\",\"datePublished\":\"2017-09-15T12:01:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg\",\"width\":700,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323","og_locale":"en_US","og_type":"article","og_title":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR","og_description":"Verastem Inc (NASDAQ:VSTM) announced recently that its new drug to treat selected blood cancer indications have met the essential goal of the late-stage study. The [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-09-15T12:01:30+00:00","og_image":[{"width":700,"height":500,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial","datePublished":"2017-09-15T12:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg","keywords":["NASDAQ:VSTM","Verastem Inc (NASDAQ:VSTM)","Verastem Inc."],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323","url":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323","name":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg","datePublished":"2017-09-15T12:01:30+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/Verastem.jpg","width":700,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/verastem-inc-nasdaqvstm-blood-cancer-program-succeeds-in-final-phase-trial-40323#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Verastem Inc (NASDAQ:VSTM) Blood Cancer Program Succeeds In Final Phase Trial"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40323"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40323\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40324"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40323"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}